Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Affectis Pharmaceuticals AG Receives research grant from the State of Bavaria technology program

July 8, 2009 - Press Release

Martinsried, Germany - Affectis Pharmaceuticals announced today that it has been awarded a €550.000 grant from the Bavarian Technology Promotion Program (BayTP) of the Bavarian Ministry of Economics. For a period of two years, the grant will fund the identification and characterization of novel drug candidates for the treatment of major depression.

Depression is a disabling disease that affects more than 121 million individuals globally, according to the World Health Organization (WHO). Current therapies fail to address unmet medical needs such as faster onset of action, better side-effect profile, and improved long- term efficacy. Untreated depression has a significant impact by adversely affecting a patient´s daily life and increasing the risk of suicide.

Herbert Stadler, CEO and co-founder of Affectis stated: 'We are pleased to have received this highly competitive grant from BayTP. The funds will accelerate the development of three innovative drug candidates that aim to address the needs of patients suffering of depression.'

Contacts for Affectis Pharmaceuticals AG:
Luc St-Onge
Fraunhoferstr. 13
82152 Martinsried, Germany
Tel: +49 (0)89 - 893 2811 100
Fax: +49 (0)89 - 893 2811 111

Ines-Regina Buth
Platz vor dem Neuen Tor 2
10115 Berlin, Germany
Tel: +49 (0)30 2363 2768
Fax: +49 (0)30 2363 2769

Notes to Editors

About Affectis Pharmaceuticals AG:
Affectis is a biopharmaceutical company implementing novel concepts for the treatment of psychiatric disorders and inflammatory diseases. The Company has unique capabilities to discover and develop drugs based on pioneering findings in the field of depression, schizophrenia, and inflammation. These drugs address the increasing need for more comprehensive and faster-acting antidepressants with fewer side effects. Affectis started operations in 2004 as a spin-off from the renowned Max-Planck-Institute of Psychiatry, a world leader in the field of psychiatric research. A strong team of executives and scientists with long-term industry experience contribute to Affectis’ progress. The Company raised its third round of venture financing in October 2006, led by AESCAP Venture. Affectis is based in Munich, Germany.

For more information, please visit our website at:

Publisher Contact Information:

Affectis Pharmaceuticals AG
+49 (0)89 - 893 2811 100

Company profile of Affectis Pharmaceuticals AG
Past press releases of Affectis Pharmaceuticals AG.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jan 10€20.0MBusiness applications
Jan 10€20.0MBiotechnology
Jan 10€13.5MArtificial Intelligence
Jan 9€4.0MSoftware development
Jan 9N/AInternet services
Jan 9€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.